Rep. April McClain Delaney Unloads STERIS plc (NYSE:STE) Stock

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 24th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

STERIS Price Performance

STE opened at $233.17 on Wednesday. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $22.72 billion, a P/E ratio of 29.40 and a beta of 0.91. The stock has a 50-day moving average price of $213.64 and a 200-day moving average price of $225.91. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities analysts predict that STERIS plc will post 11.17 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be paid a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 1.2%. This is an increase from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend is Friday, September 4th. STERIS’s dividend payout ratio is presently 31.78%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock valued at $3,114,882,000 after buying an additional 73,014 shares during the last quarter. State Street Corp grew its holdings in STERIS by 6.0% in the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock worth $1,169,957,000 after acquiring an additional 260,001 shares during the last quarter. Geode Capital Management LLC grew its holdings in STERIS by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after acquiring an additional 14,151 shares during the last quarter. Orbis Allan Gray Ltd increased its position in shares of STERIS by 5.6% in the fourth quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock valued at $570,296,000 after acquiring an additional 120,200 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of STERIS by 25.7% during the first quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock valued at $411,995,000 after acquiring an additional 380,504 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. UBS Group began coverage on shares of STERIS in a research report on Tuesday, July 28th. They issued a “buy” rating and a $275.00 target price on the stock. KeyCorp lowered their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen cut STERIS from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a report on Thursday, May 21st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average target price of $277.25.

Insider Transactions at STERIS

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director owned 38,964 shares in the company, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the sale, the chief executive officer owned 63,647 shares in the company, valued at approximately $13,493,164. This represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 7,328 shares of company stock worth $1,554,051. Company insiders own 1.12% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.